University of Florida
Latest From University of Florida
Sarepta licenses gene therapy candidate from Lacerta, also makes equity investment. Neuren licenses North American rights to rare disease drug trofinetide to Acadia.
University researchers will examine adenosine receptor modulator technology’s potential in C. difficile infection and atherosclerosis. CRISPR Therapeutics is partnering with University of Alabama-Birmingham to evaluate gene-editing procedures in Friedreich’s ataxia.
Believing biomedical research at Duke is “under fished” compared to the ponds in San Francisco and Boston, Duke’s institutional CRO looks to provide clinical trial design and other services to help tech transfer along. Plus, recent tech transfer deals include AbbVie, Calimmune and China’s Yisheng.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in August 2016.